Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MT-7117 low dose
DRUG
2 trials
Sponsors
Tanabe Pharma America, Inc.
Conditions
EPP
Erythropoietic Protoporphyria (EPP)
XLP
Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Completed
NCT03520036
Tanabe Pharma America, Inc.
Erythropoietic Protoporphyria (EPP)
Start: 2018-07-05
End: 2019-09-28
Updated: 2025-12-31
Phase 3
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Completed
NCT04402489
Tanabe Pharma America, Inc.
EPP, XLP
Start: 2020-06-01
End: 2022-07-26
Updated: 2025-12-30
Related Papers
Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon
Pharmacology Research & Perspectives
2025-01-31
Absorption, metabolism, and excretion of [<scp><sup>14</sup>C</scp>]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
Pharmacology Research & Perspectives
2023-04-20
8 citations
Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist
European Journal of Clinical Pharmacology
2023-04-15
9 citations
Dersimelagon in Erythropoietic Protoporphyrias
New England Journal of Medicine
2023-04-12
27 citations